Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Free Report) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright lowered their target price on shares of Can-Fite BioPharma from $34.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, October 24th.

View Our Latest Report on CANF

Can-Fite BioPharma Stock Performance

CANF stock opened at $1.99 on Thursday. The firm has a 50 day moving average price of $2.10 and a 200-day moving average price of $2.41. Can-Fite BioPharma has a 52-week low of $1.52 and a 52-week high of $4.60. The firm has a market capitalization of $7.03 million, a price-to-earnings ratio of -0.77 and a beta of 1.48.

Can-Fite BioPharma (NYSE:CANFGet Free Report) last released its earnings results on Thursday, November 30th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). Can-Fite BioPharma had a negative net margin of 1,146.62% and a negative return on equity of 143.59%. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.20 million. As a group, sell-side analysts forecast that Can-Fite BioPharma will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Can-Fite BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Schechter Investment Advisors LLC bought a new stake in Can-Fite BioPharma in the 4th quarter worth approximately $44,000. Virtu Financial LLC bought a new stake in Can-Fite BioPharma in the 2nd quarter worth approximately $52,000. Finally, Armistice Capital LLC bought a new stake in Can-Fite BioPharma in the 1st quarter worth approximately $756,000. Institutional investors own 1.54% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Featured Articles

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.